Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

This study has been completed.

First Received: May 2, 2002 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Center for Research Resources (NCRR)
Collaborator:	Urological Research Foundation
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00035217

Purpose

There is controversy concerning the preferred treatment for men with localized prostate cancer with regard to the relative effectiveness of different treatments in controlling the cancer and how different treatments affect the patient's quality of life. The purpose of this research is to describe the disease course of prostate cancer and to determine the effectiveness, potential complications, and quality of life after different treatments in men with prostate cancer detected via screening with prostate-specific antigen (PSA) and/or digital rectal examination

Condition
Prostate Cancer

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Retrospective/Prospective Study
Official Title:	Follow-Up Study for Men Diagnoses With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	40 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Men with prostate cancer diagnosed through the PSA screening study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035217

Locations

United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Urological Research Foundation

More Information

No publications provided

Study ID Numbers:	NCRR-M01RR00036-0838
Study First Received:	May 2, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00035217 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 22, 2009